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Harnessing the immune system in glioblastoma
Nicholas F. Brown1,2, Thomas J. Carter1,3, Diego Ottaviani1 and Paul Mulholland1,3
Glioblastoma is the most common primary malignant brain tumour. Survival is poor and improved treatment options are urgently
needed. Although immunotherapies have emerged as effective treatments for a number of cancers, translation of these through to
brain tumours is a distinct challenge, particularly due to the blood–brain barrier and the unique immune tumour microenvironment
afforded by CNS-speciﬁc cells. This review discusses the immune system within the CNS, mechanisms of immune escape employed
by glioblastoma, and the immunological effects of conventional glioblastoma treatments. Novel therapies for glioblastoma that
harness the immune system and their current clinical progress are outlined, including cancer vaccines, T-cell therapies and immune
checkpoint modulators.
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INTRODUCTION
Glioblastoma is the most common malignant primary brain
tumour in adults.1 Survival is poor, with a median survival of
14.6 months with standard treatment of surgical debulking
followed by external-beam radiotherapy with concurrent temo-
zolomide (TMZ) chemotherapy and adjuvant TMZ chemotherapy.2
In the last decade, clinical trials investigating targeted therapies
have failed to demonstrate any signiﬁcant improvement in
survival, and innovative new treatments are urgently needed.3
Recently, focus has shifted towards novel strategies that modulate
the immune response towards the tumour and the surrounding
tumour microenvironment.
Recognition and eradication of malignant cells via immune
surveillance of tumour-associated antigens (TAAs) is a key function
of the immune system.4 TAAs typically represent peptides which
are present within tumour cells but usually absent in the
surrounding normal tissue. In glioblastoma, these antigens most
commonly fall into three main classes; (i) aberrantly expressed
non-mutated self-antigens, (ii) mutated self-antigens and (iii)
unique antigens or neo-antigens - novel peptide sequences which
are the result of somatic mutations in the cancer genome.5
Tumours manipulate the immune system to avoid detection of
TAAs and to facilitate their own growth and survival.6
Immunotherapy aims to harness the immune system against
tumours, with breakthroughs observed in a number of cancers,
most notably malignant melanoma and haematological malig-
nancies. However, translating these approaches into therapies for
primary brain tumours represents a distinct challenge due the
unique tumour microenvironment and distinctive immune system
within the CNS.
The CNS was traditionally considered immune privileged due to
(i) the presence of the blood–brain barrier (BBB) that restricts
access to immune cells, (ii) an absence of conventional lymphatic
drainage restricting the trafﬁcking of antigens to lymph nodes,7
(iii) a scarcity of specialised antigen-presenting cells,8 and
iv) downregulation of the major histocompatibility complex
(MHC) expression in normal brain parenchyma, limiting antigen
presentation.9 In recent years, this dogma has been eroded with
substantial evidence now demonstrating that these interlinked
factors tightly regulate a fully functional, innate and adaptive
immune system within the CNS (Table 1).
In this review, we describe the features of the immune system
in the CNS, discuss the immune evasion strategies of glioblastoma,
the molecular properties of its microenvironment, and the current
clinical evidence supporting a role for immunomodulation in the
treatment of glioblastoma.
GLIOBLASTOMA TUMOUR MICROENVIRONMENT AND
MECHANISMS OF IMMUNE ESCAPE
Glioblastoma arises from glial cells, with surrounding brain
parenchyma comprising CNS-speciﬁc cells including astrocytes,
neurons and microglia, and a distinctive extracellular matrix (ECM)
composition.10 Glioblastoma induces a TME characterised by
immunosuppressive cytokines secreted by tumour cells, microglia
and tumour-associated macrophages (TAMs). These factors,
notably interleukin-6, interleukin-10, transforming growth factor-
beta (TGF-β), and prostaglandin-E collectively inhibit both the
innate and adaptive immune systems with suppression of NK
activity and T-cell activation and proliferation, induction of T-cell
apoptosis, downregulation of MHC expression, and skew of TAMs
towards an M2 (immunosuppressive) phenotype.11 The TME is also
characterised by tissue hypoxia provided by irregular vascularity
and high-tumour oxygen consumption. Tissue hypoxia activates
the immunosuppressive STAT3 pathway, leading to hypoxia-
inducible factor-1 alpha (HIF-1α) synthesis, activation of regulatory
T cells (T-regs) and production of vascular endothelial growth
factor (VEGF),11 which can inhibit the maturation and function of
dendritic cells. These mechanisms of immune escape are
discussed below in more detail and summarised in Fig. 1.
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Extracellular matrix composition
ECM proteins commonly found in abundance in peripheral tissues
including collagens, laminins and ﬁbronectin are typically only
associated with vascular basement membranes within the CNS.
Instead, predominant ECM proteins in the glioma TME include
glycoproteins, hyaluronic acid and heparan sulphate proteogly-
cans (HSPGs), which may be concentrated in cancer stem cell
niches.12 HSPGs, in particular, are upregulated in glioblastoma13
and cause retention of heparin-binding angiogenic growth factors
such as ﬁbroblast growth factor (FGF) and VEGF, the local release
of which promotes tumour angiogenesis and progression.14
Furthermore, glioma vasculature can upregulate the vessel-
associated macromolecules periostin and tenascin C (TNC), which
can promote tumour survival.15 These macromolecules can also
promote immune evasion with TNC shown to block T-cell
movement across glioma-associated blood vessels, preventing
their migration into brain parenchyma.16 Periostin, when secreted
by glioma stem cells, is able to promote recruitment of tumour
promoting macrophages from peripheral circulation.17
Macrophages and microglia
Tumour-associated macrophages (TAMs), along with the resident
CNS microglia, can constitute up to 30% of the tumour mass.10
Transcriptome analysis of TAMs has found that they may possess
markers consistent with both M1 (classically activated or
immunopermissive) and M2 (alternatively activated or immuno-
suppressive) phenotypes, incongruous with the traditional M1/M2
dichotomy.18 TAM populations can be described both functionally
and spatially. For example, CNS-resident microglia exist within
the TME alongside distinct populations of bone marrow-derived
macrophages (outlined in Table 1),19 and recent research has
suggested that within the TME, bone marrow-derived macro-
phages may localise preferentially to the perivascular niche, while
resident microglia localise to peritumoural regions.20 Accumula-
tion of TAMs expressing CD163 (haemoglobin scavenger receptor)
and CD204 (macrophage scavenger receptor), considered ‘M2′
phenotype markers, increases as tumour grade increases.21 In
glioblastoma, higher CD163 TAM expression correlates with
poorer outcomes.11 Cancer stem cells in glioblastoma are able
to recruit TAMs by overexpression of the macrophage/microglia
cytokine colony-stimulating factor-1 (CSF-1).22 This induces a pro-
tumourigenic microenvironment via release of immunosuppres-
sive factors such as IL-10 and overexpression of the indoleamine
2,3-dioxygenase (IDO) enzyme.17,23 M2-TAMs also lack expression
of key T-cell co-stimulation molecules24 and drive both tumour
angiogenesis and resistance to anti-VEGF agents. Angiogenesis is
driven through production of pro-angiogenic molecules including
VEGF and FGF, with resistance to anti-angiogenics due to
upregulation of alternative angiogenic pathways and stimulation
of pericytes to proliferate in the perivascular niche. Pericytes are
perivascular cells responsible for modulating blood ﬂow, vessel
permeability and remodelling, and their proliferation stabilises
new vessels.25,26 TAMs can also enhance the invasiveness of
glioma stem cells (GSCs) via the TGF-β1 signalling pathway.27
Further evidence, incongruous with the M1/M2 dichotomy, is
that blockade of CSF-1R on the macrophage surface does not
deplete glioblastoma TAMs in vivo, but leads to reprogramming
of TAMs away from immunosuppressive phenotypes.28 Other
emerging evidence includes the discovery of a link between tissue
hypoxia and macrophage polarisation; with M1 macrophages
present within normoxic tumour regions and M2 macrophages
present in areas of hypoxia.29 These ﬁndings support the view
that macrophage polarisation is not simply location dependent
but instead dependent on distinct signals present in the local
microenvironment.30 TAMs retain both plasticity and the ability to
undergo reprogramming;31 characteristics which are potentially
exploitable for therapeutic beneﬁt.32
Downregulation of MHC
An effective T-cell immune response requires antigen presentation
and subsequent recognition, which is dependent on the co-
expression of the human MHC proteins. Comparative analyses of
gene expression proﬁles suggest that invading glioblastoma cells
are able to escape immune recognition by downregulating
expression of MHC molecules.33 The role of antigen presentation
within the CNS is thought to fall primarily to the resident
Table 1. Current understanding of the CNS immune system
Characteristic Current understanding
Blood–brain barrier Leukocyte entry into the CNS is mediated by adhesion signals on endothelial cells (ECs) of the BBB. Limited
expression of adhesion signals on ECs in healthy CNS results in low immune surveillance.157 In disease
processes, inﬁltration of speciﬁc immune cell subsets is observed, which may be driven by BBB ECs or by
immune cells within the CNS.158 While naive T cell are absent within the CNS, activated T cells cross the BBB
as patrolling memory T cells and regulatory T-cells; preventing inappropriate inﬂammation8 and facilitating
myelin regeneration.159
Lymphatic drainage Extracellular ﬂuid in the CNS is composed of cerebrospinal ﬂuid (CSF) and interstitial ﬂuid (ISF). CSF is mainly
contained within the ventricular system and subarachnoid space, and drains directly into deep cervical and
lumbar lymph nodes via lymphatic vessels associated with the nasal mucosa, dura mater and nerve roots.7,
160 ISF is found in the extracellular spaces of CNS parenchyma and drains into cervical lymph nodes via
intramural perivascular drainage pathways in cerebral artery walls.7, 160 Both CSF and ISF may communicate
within the brain parenchyma via the glial lymphatic system, a perivascular channel system formed by
astroglial cells which removes waste proteins and macromolecules.161, 162 Tissue metabolites found within
the glial lymphatic system trafﬁc to deep cervical and lumbar lymph nodes via CSF. Within these lymph
nodes, T cells may become primed and activated to recognise CNS-speciﬁc antigens.7, 156
Antigen-presenting cells Three subsets of dural macrophage populations have been identiﬁed, named for their location in the CNS.163
Meningeal macrophages and choroid plexus macrophages are bone marrow derived, while perivascular
macrophages appear to originate from haematopoietic stem cells in the embryonic yolk, an origin they share
with microglial cells.7 These macrophage populations can all act as antigen-presenting cells. The position of
perivascular macrophages allows them to sample both blood and CNS ISF, implying a possible role in
communication between the CNS and periphery.163 As well as this, there is evidence from in vivo models that
brain parenchyma is completely screened every few hours by resting microglia.164
Antigen presentation via
MHC expression
CNS antigen presentation is thought to occur at the BBB by microglia, dural macrophages or dendritic cells at
so-called CNS ‘immune gateways’ where MHC is expressed.156 These gateways also act as entry ports for
activated T cells, inﬂux of which can be followed by monocyte recruitment that ampliﬁes inﬂammatory
reactions within CNS.157
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microglia, with supporting evidence in vivo demonstrating that
microglia are able to cross-present tumour antigens to CD8+
T cells via MHC Class I.34 However, the presence of immunosup-
pressive cytokines such as IL-10 and TGF-ß within the glioblas-
toma TME cause microglia to lose MHC expression.11,35 Pericytes
may also play a role in antigen presentation within the CNS, and
pericyte MHC Class II expression is shown to increase in response
to inﬂammatory cytokine release.36 In the TME, pericytes in
contact with glioblastoma cells possess immunosuppressive
functions evidenced by changes including a reduction in MHC
expression and T-cell co-stimulatory signals.37 Low levels of MHC
Class I molecules are also found on glioblastoma cancer stem
cells, rendering them resistant to T-cell-mediated killing, and thus
contributing towards tumour initiation, progression and resistance
to therapy.38
T lymphocytes
In patients with glioblastoma, increased T-cell inﬁltration is found
in both tumour (tumour-inﬁltrating lymphocyte; TIL) and brain
parenchyma.39 Studies of human tumour samples have shown
that this inﬂux is counteracted with a number of events that
evade the immune response including further downregulating
MHC to prevent antigen presentation,40 increasing expression of
the inhibitory protein programmed death ligand-1 (PD-L1),41 and
increased recruitment of immunosuppressive regulatory T cells
(T-regs) which express co-inhibitory molecules including cytotoxic
T lymphocyte-associated protein 4 (CTLA-4) and programmed
death receptor 1 (PD-1).42,43 Fourfold more T-regs are found in
human glioblastoma samples than benign pituitary adenomas and
meningiomas, with CTLA-4 expression on these T-regs threefold
that on T-regs in peripheral blood.42 PD-L1 expression on
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Fig. 1 Immune gateways (left). In addition to the resident microglia, there are three distinct macrophage populations within the CNS present
at so-called ‘immune gateways’ that act as ports of entry for activated T cells into the CNS. Perivascular macrophages, derived from the
embryonic yolk sac, are located around parenchymal vessels (top). The other two populations, derived from bone marrow, are located
in the meningeal spaces (middle) and the choroid plexus (bottom) (adapted from ref. 156). Immune evasion in glioblastoma (right): the
immunosuppressive tumour microenvironment (TME) of glioblastoma is the result of complex interactions between tumour cells, microglia,
tumour-associated macrophages (TAMs), components of the extracellular matrix and tumour inﬁltrating lymphocytes (TILs), which are
predominantly regulatory in phenotype (T-regs). Hypoxia promotes angiogenesis of abnormal blood vessels, further driving tumour growth
(adapted from ref. 10)
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circulating monocytes is signiﬁcantly higher in patients with
glioblastoma compared to healthy controls, while expression in
tumour inﬁltrating monocytes is, on average, twice that of
circulating monocytes from the same patient.41
IMMUNOLOGICAL EFFECTS OF STANDARD THERAPY
Standard therapy for patients diagnosed with glioblastoma
consists of maximal safe debulking surgery, followed by radio-
therapy and temozolomide chemotherapy (RT-TMZ).2 In addition,
high doses of glucocorticoids are frequently administered to
reduce tumour-associated and radiotherapy-induced cerebral
oedema. These therapies may potentially both augment or
diminish immune responses.
Radiotherapy, chemotherapy and glucocorticoid therapy are
independently immunosuppressive. Approximately 70% of
patients experience clinically signiﬁcant reductions in their
circulating CD4+ lymphocyte counts following standard treat-
ment, persisting for up to a year and associated with early tumour
progression.44 TMZ-induced lymphopenia is considered a sig-
niﬁcant limitation to clinical translation of immunotherapies.44
Radiation induces M2 macrophages and activation of TGF-β.45–47
RT-TMZ has been shown to increase PD-L1 expression in
preclinical glioblastoma models, and acquired resistance to
radiotherapy has been overcome by PD-L1 blockade in cancer
models.48,49 Further, as well as depleting systemic lymphocyte
counts, RT-TMZ also tilts the balance between regulatory and
effector peripheral blood lymphocytes towards an immunosup-
pressive state.50,51 Corticosteroids dampen inﬂammatory cyto-
kines, deplete T and B lymphocytes, reduce the effectiveness of
anti-tumour therapy in rodent models, and their use is associated
with poorer survival in patients with glioblastoma.52–54
Conversely, standard treatments have been shown to induce
immune responses through favourable modulation of the TME
and ‘immunogenic cell death’. In addition to cancer cell death
through DNA damage and free radical generation, radiation
activates an interconnected chain of processes in the TME
including inﬂammation, hypoxia, revascularisation, ECM remodel-
ling and ﬁbrosis.55 Radiation induces pro-inﬂammatory cytokines
such as TNF-α, IL-1β, IFN-γ,CXCL9, CXCL10 and CXCL16 which
recruit T cells.56–58 Sublethal doses of radiation promotes
phenotypic changes in tumour cells that promote T-cell recogni-
tion and killing, including increasing expression of MHC Class I,
co-stimulatory receptors, death receptors and heat-shock pro-
teins.56,59–63 Further, evidence suggests RT is able to modulate
the tumour vasculature and increase BBB permeability, leading
to increased TIL trafﬁcking.64 Abscopal responses (tumour
response distant from the radiation ﬁeld), while unusual, illustrate
the potential for radiation-induced anti-tumour immunity.56,65
TMZ chemotherapy induces hypermutation of the tumour, and
increased mutational load correlates with response to immune
checkpoint inhibitors in a number of cancers including melanoma,
NSCLC and urothelial cancers.66–71 Durable responses to nivolu-
mab were observed in a case report of two patients with high
mutational burden glioblastoma resultant from biallelic mismatch
repair deﬁciency.72 In murine glioma models, TMZ has been found
to increase priming of tumour antigen-speciﬁc CD4 and CD8
T cells.73 While associated with early progression, in one study of
patients with glioblastoma, lymphopenia following TMZ was
associated with better survival.74 Clinical evidence of immune-
stimulation has been observed in vaccine trials of a dendritic cell
vaccination where pre-treatment with RT-TMZ increased tumour
antigen-speciﬁc T cells.75
This delicate balance between stimulation or suppression of
immune responses by standard therapies is still being elucidated.
Potentially, careful timing to permit lymphocyte recovery, dose
modiﬁcation or local rather than systemic administration of
standard therapies may permit immune priming of tumours
without negation due to immunosuppressive sequelae.63,76
Recently, adding tumour-treating ﬁelds (alternating electric ﬁelds
delivered via a transducer array applied to the scalp) to standard
therapy has been shown to prolong survival.77 Whether this may
enhance immune responses is unknown and further clinical trials
are underway (Table 2).78
IMMUNOTHERAPEUTIC APPROACHES AND CLINICAL
PROGRESS IN GLIOBLASTOMA
Early trials in glioblastoma largely administered systemic or intra-
tumoural cytokines, with development limited by signiﬁcant
toxicity with only modest clinical beneﬁt.79,80 Arguably the most
promising of these, IFN-γ, possesses anti-proliferative, anti-
angiogenic and pro-apoptotic functions and is able to increase
antigen presentation through upregulation of MHC Class I and II,
as well as mediating immune cell inﬁltration.81 However, IFN-γ also
induces PD-L1 expression as well as promoting T-reg develop-
ment. It is also possible that glioblastoma cells exploit IFN- γ
through low level upregulation to induce PD-L1 expression and
escape immune cell detection.82 These factors may help to explain
why these early immunotherapeutic approaches were disappoint-
ing,83 and why current focus has moved towards therapies that
either prime immune cells to target-speciﬁc tumour-associated
antigens, or modulate the TME to reverse immune escape (Fig. 2).
As yet, only two phase III trials have completed: the EGFRvIII-
targeted vaccine rindopepimut in newly diagnosed glioblastoma;
and the checkpoint inhibitor nivolumab in relapsed glioblastoma;
with neither demonstrating survival advantage.84,85 Phase III trials
of checkpoint inhibitors and dendritic cell vaccines are ongoing,
with a large number of agents in earlier stages of clinical
development including peptide vaccines, adoptive T-cell thera-
pies, oncolytic viruses (OV) and combination therapies (Table 2).
Immune checkpoint inhibitors
The amplitude and quality of T-cell responses are regulated by
a balance of co-inhibitory and co-stimulatory signals, termed
immune checkpoints.66 Tumours exploit these safety mechanisms
to render T cells inactive within the TME. In glioma, higher
expression of PD-L1 expression correlates with increasing tumour
grade and is associated with poor survival in glioblastoma.
A total of 88–100% of glioblastomas express PD-L1, and it is
also expressed on microglia and TAMs within the TME.11,86–89
Checkpoint inhibitors are monoclonal antibodies that either
inhibit the activity of immune checkpoints, or mimic ligand
binding. Checkpoint inhibitors targeting PD-1 (nivolumab/pem-
brolizumab), PD-L1 (atezolizumab/durvalumab/avelumab) and
CTLA-4 (ipilimumab) are licensed for use in various cancers, with
pembrolizumab licensed by the FDA for mismatch repair deﬁcient
and microsatellite instability-high tumours regardless of the tissue
of origin. Although overall nivolumab was overall found not
to improve survival in patients with relapsed glioblastoma, a small
subset of patients did have a durable response, and analysis of
their tumour biomarkers and immune responses may guide future
trials.84 Initially within this trial, an exploratory cohort of patients
were treated with nivolumab and ipilimumab (licensed for use
in melanoma), but this combination was less well tolerated
compared to nivolumab monotherapy and so was not included in
the main trial.90 Nivolumab is currently under investigation in
combination with radiation ± TMZ in newly diagnosed patients,
and trials of other checkpoint inhibitors are ongoing or awaiting
ﬁnal results (Table 2). Early interim reports from phase II trials
of pembrolizumab in relapsed glioblastoma and durvalumab
with bevacizumab in newly diagnosed/relapsed glioblastoma are
encouraging.91,92 Checkpoint inhibitors are associated with a
variety of immune-mediated toxicities.93 Notably for glioblastoma,
transient increases in tumour size can occur due to inﬂammatory
inﬁltrates, which within the ﬁxed size of the cranial vault may
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cause raised intracranial pressure, requiring urgent medical or
surgical intervention.94
Tumour vaccines
Cancer vaccination is achieved in several ways (Fig. 2). The ﬁrst
involves administering a tumour-speciﬁc antigen (or combination
of antigens), which can then be trafﬁcked to antigen-presenting
cells for presentation to T cells to elicit an immune response.
Drawbacks are that it is HLA subtype speciﬁc, and that it relies
upon expression of the speciﬁc antigen within the patient’s
tumour.95 The second method is to collect autologous dendritic
cells, prime them ex vivo with the patient’s tumour antigens,
and then administer them back into the patient intradermally;
a process referred to as dendritic cell vaccination.39 The only
vaccine therapy to have completed evaluation is rindopepimut,
an EGFRvIII-targeted vaccine, which did not improve survival
when administered alongside standard therapy in patients with
newly diagnosed EGFRvIII mutant glioblastoma.85 However, an
exploratory outcome found improved survival in patients with
signiﬁcant residual disease. Various vaccines are in earlier stages
of development, and discussed more fully elsewhere, with several
promising candidates.96 HSPPC-96, an autologous vaccine derived
from antigenic tumour peptides bound to heat-shock protein,
reported a promising 6 month survival rate of 90% in a phase II
trial in 41 patients with recurrent glioblastoma.97 AFTV is an
autologous vaccine derived from formalin-ﬁxed tumour samples
which reported a favourable 3 year survival rates of 38% in a
phase I/IIa trial in 24 patients with newly diagnosed glioblastoma
treated with AFTV in addition to standard therapy.98 A peptide
vaccine that selected 4 of 14 pre-selected antigens based upon
pre-existing antigen-speciﬁc IgG responses has demonstrated the
feasibility of personalised vaccines in a phase I trial in 12 patients
with recurrent glioblastoma.99
T-cell therapies
Chimeric antigen receptor T-cell (CAR-T) therapy is an adoptive
cell therapy in which autologous T cells are isolated, genetically
modiﬁed to express chimeric receptors targeting tumour antigens,
and re-administered to the patient subsequent to lymphodepletive
chemotherapy. This strategy bypasses the need for MHC-dependent
co-stimulation (Fig. 2) due the fusion of antigen-binding domain to
T-cell activation and co-stimulatory domains.100 Impressive clinical
responses in patients with treatment-refractory lymphoma treated
with CD19-targeted CAR-T cells have led to the recent licensing of
the ﬁrst approved CAR therapies.101,102 However, deaths from
cytokine release storms have occurred due to the potency of the
immune response generated.103 In contrast to B cell aplasia which is
tolerable, in solid tumours on-target off-tumour toxicity may cause
Table 2. Examples of ongoing clinical trials of immunotherapies in glioblastoma. Identiﬁer from www.clinicaltrials.gov
Target Therapy Setting Phase Identiﬁer
Checkpoint inhibitors
PD-1 Radiotherapy+ temozolomide+ either nivolumab or placebo Newly diagnosed II NCT02667587
Radiotherapy+ either nivolumab or temozolomide Newly diagnosed III NCT02617589
Radiotherapy+ temozolomide+ pembrolizumab Newly diagnosed I/II NCT02530502
Nivolumb+ either high or low dose bevacizumab Relapsed II NCT03452579
Pembrolizumab ± bevacizumab Relapsed II NCT02337491
Pembrolizumab+ surgery Relapsed II NCT02337686
PD-1+ CTLA-4 Ipilimumab and/or nivolumab in combination with temozolomide Newly diagnosed I NCT02311920
Nivolumab vs. bevacizumab; Nivolumab ± ipilimumab Relapsed III NCT02017717
Tumour-treating ﬁelds+ nivolumab ± ipilimumab Relapsed II NCT03430791
4-1BB+ LAG-3+ PD-1 Anti-LAG-3 or urelumab ± nivolumab Relapsed I NCT02658981
Vaccines
Dendritic cell vaccine DCVax-L or placebo with radiotherapy+ temozolomide Newly diagnosed III NCT00045968
ICT-107 or placebo with radiotherapy+ temozolomide Newly diagnosed III NCT02546102
ADCTA-G+ radiotherapy+ temozolomide Newly diagnosed II NCT02772094
ICT-121 Relapsed I NCT02049489
Peptide vaccine Temozolomide+ IMA950+ Poly-ICLC (after radiotherapy) Newly diagnosed I/II NCT01920191
Bevacizumab ± DSP-7888 Relapsed II NCT03149003
Temozolomide+ APVAC+ Poly-ICLC+GM-CSF (after radiotherapy) Newly diagnosed I NCT02149225
Mutation-derived tumour antigen vaccine+ Tumour-treating
ﬁelds+ temozolomide
Newly diagnosed I NCT03223103
Adoptive cell therapies
T cell CMV-speciﬁc cytotoxic T cells+ temozolomide ± surgery Relapsed I/II NCT02661282
T cell/CAR-T Anti-Her2 CAR CMV-speciﬁc T cells Relapsed I NCT01109095
CAR-T Anti-IL13Rα2 CAR-T cells Relapsed I NCT02208362
CAR-T Intracerebral Anti-EGFRvIII CAR-T Relapsed I NCT03283631
CAR-T Intracranial Anti-Her2 CAR-T Cells Relapsed I NCT0242297
CAR-T Anti-EGFRvIII CAR-T cells Relapsed Pilot NCT02209376
Viral therapy
Adenovirus Delta-24-RGD adenovirus Recurrent I/II NCT01582516
Adenovirus DNX-2401+ temozolomide Recurrent I NCT01956734
Adenovirus DNX-2401+ pembrolizumab Recurrent II NCT02798406
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critical organ dysfunction, which limits use to antigens that are
highly tumour speciﬁc.103,104 In addition, the immunosuppressive
TME in solid tumours reduces CAR-T trafﬁcking to the tumour, and
subsequent proliferation and persistence.104
Early-phase clinical trials in glioblastoma are underway inves-
tigating CAR-T therapies targeting IL-13 receptor alpha 2
(IL-13Rα2), epidermal growth factor receptor variant III (EGFRvIII)
and human epidermal growth factor receptor 2 (Her-2) (Table 2).
IL-13Rα2 is abundantly expressed on the majority of glioblastomas
in both differentiated and stem-cell like cells, with limited
expression in normal brain.105 EGFRvIII is a mutated form of
wild-type EGFR that is tumour-speciﬁc and present in approxi-
mately one quarter of patients with glioblastoma.106 Reported
frequency of Her-2 expression in glioblastoma varies greatly from
0 to 42%.107–109 Early reports highlight striking responses.110–112
Other adoptive cell therapy strategies in early clinical develop-
ment include cytotoxic T lymphocytes speciﬁc for antigens such
as cytomegalovirus (present in over 90% of glioblastoma tumours,
but not surrounding brain), lymphokine-activated cytotoxic T cells
and natural killer cells.113–115
Current approaches to enhancing CAR-T cell therapy in solid
tumours include strategies to incorporate additional intracellular
signalling domains that enhance proliferation and persistence
(e.g. IL-12-secreting armoured CARs) and provision of user control
over T-cell immune activation to control toxicity, for example
conditional CARs that require small molecule activation.116 CARs
have also been inserted into other immune cell subsets (e.g. CAR-
NK cells) with promising preclinical reports.117,118
Oncolytic viruses
OVs are native or genetically engineered viruses that promote anti-
tumour responses through selective replication within cancers cells
resulting in cell lysis or immunogenic cell death.119,120 Glioblas-
toma is susceptible to OVs in preclinical models.121–123 Overcoming
viral exclusion by the blood–brain barrier has been achieved by
direct tumour injection of OVs, or by using viruses known to have
good CNS penetration (e.g. parvovirus).124 Early phase trials have
established OVs as safe in glioblastoma, but as yet efﬁcacy has
been modest.125 Current strategies are focussing on targeted OVs
and combination therapy (Table 2).126,127
Bevacizumab
Bevacizumab is an anti-VEGF monoclonal antibody. It is used as a
steroid-sparing agent in glioblastoma for the management of
cerebral oedema, although has not demonstrated a survival
beneﬁt and is licensed outside of the EU for this indication.128–130
As well as modulating vasculature, VEGF inhibits dendritic cell
maturation, antigen presentation, and lymphocyte trafﬁcking into
tumours.131,132 As such, bevacizumab is ﬁnding a new role as
an adjunct to immunotherapies, possibly via the normalisation
of tumour vasculature and induction of high endothelial venule
(HEV) formation within tumours, both of which facilitate T-cell
inﬁltration and activation.133,134 Anti-VEGF therapy induces
transient tumour vessel normalisation, but studies support that
lower doses than those routinely used in clinical practice result
in a longer ‘normalisation window’.135 Combination ipilimumab
and bevacizumab in patients with melanoma suggests VEGF
inhibition enhances anti-tumour immune responses.136 Several
combination anti-VEGF/immunotherapy studies are underway
in glioblastoma (Table 2), with interim data from a phase II trial
of the anti-PD-L1 agent durvalumab in combination with
bevacizumab reporting apparent clinical activity in a subset of
bevacizumab-naive patients.74
CONCLUSIONS AND FUTURE DIRECTIONS
Cancer treatment is moving towards personalised care with the
ability to therapeutically target-speciﬁc tumour characteristics.
Immunotherapies currently in clinical development will likely
beneﬁt a subset of patients with glioblastoma; however, no
reliable biomarker currently exists to predict these patients.
Unlike most cancers, glioblastomas rarely metastasise, affording
the unusual opportunity of potentially using localised therapy
for advanced disease.137 Based on observations in melanoma
that increased tumour burden correlates with a poorer response
to the anti-PD-1 antibody pembrolizumab,138 it is possible that
surgical debulking in glioblastoma may enhance the effectiveness
of immunotherapy by diminishing the immunosuppressive TME.
Ongoing trials of nivolumab in newly diagnosed glioblastoma that
are stratiﬁed by the extent of resection may provide insight. If so,
the role of surgery may be extended to recurrent disease (when
it is not routinely performed) as an adjunct to immunotherapy.
Various devices are available to bypass the BBB and deliver
therapies directly into a tumour or tumour cavity, reducing
systemic toxicity, and potentially modulating the TME more
favourably than systemic treatment.139–141 Intracranial administra-
tion via catheter delivery is currently under investigation in clinical
trials of CAR-T cell therapy, with case reports of clinical efﬁcacy.112
There are also new avenues being explored to augment the
efﬁcacy of immunotherapy. Recent evidence shows that distinct
gut microbial composition, or microbiome can affect and even
enhance responses to checkpoint inhibitors,142 and that depletion
of intestinal bacteria with antibiotics can diminish the patient’s
response to immunotherapy.143,144 Future breakthroughs could
manipulate the microbiome towards a status that promotes
anti-tumour immune responses.145 Another growing ﬁeld is
Fig. 2 Immunotherapeutic approaches in glioblastoma. From top: Tumour vaccines: There are two main approaches; In dendritic cell
vaccination (left) tumour cells are isolated at surgery (a), and processed to form a tumour lysate (b). Apheresis is done to isolate immature
monocytes (c), which are then activated ex vivo into immature dendritic cells (d). Finally, these dendritic cells are matured and activated using
tumour lysate and then returned to patients as intra-dermal injection (e). In peptide vaccination (right) tumour cells are isolated after surgery
(1), and then further processed to isolate tumour antigens (2). These are then artiﬁcially produced and processed into a HLA-matched vaccine
(3), which is then returned to the patient as an intradermal injection. Immune Checkpoint Inhibitors: While T-cell responses are initiated
through the interaction of MHC Class I/II bound antigen with the T-cell receptor (TCR), the amplitude and quality of this response is regulated
by a balance of co-inhibitory and co-stimulatory signals; commonly referred to as immune checkpoints. Checkpoint inhibitors function to
either mimic co-stimulatory signals or prevent co-inhibitory signals. Therapies targeting a number of checkpoints are in development,
including 4-1BB (a), CTLA-4 (b), PD-L1 (c) and PD-1 (d). T-cell therapies: In CAR-T cell therapy (left), autologous T cells are isolated and
expanded (a) and the CAR construct inserted with viral vectors (b). Autologous CAR-T cells are then returned to the patient as an infusion (c).
In adoptive cell transfer (right), following T-cell isolation and expansion (1), T cells are either activated ex vivo using lymphokines (2A) or
selected for a speciﬁc tumour antigen (2B). Cells are then expanded and returned to patients as an infusion (3). Bevacizumab: Right:
Unopposed VEGF signalling within tumours induces new blood vessel formation, inhibitors dendritic cell (DC) maturation, antigen
presentation and T-cell trafﬁcking. Left: In the presence of bevacizumab, VEGF signalling is blocked resulting in vessel normalisation, formation
of high endothelial venules (HEVs) and facilitation of T-cell trafﬁcking, augmenting response to immune checkpoint inhibitors. Oncolytic viral
therapies: Oncolytic viruses are engineered to replicate preferentially in glioblastoma cells (due to lack of tumour suppressor function). Viruses
are delivered either directly into tumours (a) or intravenously (b) if able to travel across the BBB. Within normal cells, viruses do not replicate
due to intact tumour suppressor apparatus. However, within tumour cells, viruses replicate and induce apoptosis
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thermal therapy, with evidence that hyperthermia can mediate
immunogenic cell death.146 It is also critical that the TME if fully
characterised to determine how it can be further targeted for
cancer immunotherapy. T-cell metabolism is a developing ﬁeld,
and a promising therapeutic target is IDO, a tryptophan catabolic
enzyme overexpressed in several tumour types that is thought
to create an immunosuppressive microenvironment by inhibiting
T-cell immunity.147,148
Tumour heterogeneity is well characterised in glioblastoma,
and may contribute towards immune cell heterogeneity within
tumours.149,150 Glioblastoma heterogeneity is at least partly
maintained by extracellular vesicles (EVs) that contain molecules
including DNA, RNA and proteins. The shedding and uptake of
these vesicles from tumour cells form an additional communica-
tion network capable of modulating the TME. Recent evidence
has also shown that PD-L1 is expressed on glioblastoma EVs.151,152
Further, vascular heterogeneity exists, with vessel co-option
(glioblastoma migration along existing blood vessels) occurring
alongside angiogenesis, increasing the complexity of heteroge-
neity within glioblastoma.153 Further research into these factors,
including utility of techniques such as single-cell RNA sequencing
to characterise both tumour, and immune cell heterogeneity154,155
may facilitate a future shift towards more personalised treatment.
In summary, the CNS has an active immune system and
glioblastoma employs a number of strategies to evade immune-
mediated death. To design therapies that effectively harness
the immune system against glioblastoma, a deeper understanding
of the complex interactions between tumours and the tightly
regulated immune system in the CNS is needed. Future therapies
will need to address multi-dimensional challenges including
identifying truly tumour-speciﬁc antigens to target, increasing
tumour immunogenicity, targeting the immune microenviron-
ment and controlling toxicity of therapy.
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